BNTX BioNTech SE — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$92.33

Period return

-26.14 (-22.06%)

Volume

666.1K

2026-07-21O $92.29 H $93.9 L $91.81 C $92.33MA5 $91.9MA20 $92.35MA60 $92.68MA120 $96.51

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 13 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 28.MediumBUY2 months ago
UBS: Buy
US analyst rating / recommendation change.
2026. 05. 22.MediumHOLD2 months ago
Bernstein: Market Perform
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 07.LowBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 04. 27.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 04. 10.LowBUY3 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 03. 31.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 12.LowBUY4 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $124.36 · 19 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	166,179	$14.77M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	108,258	$10.31M	0.02%	—	New position

BioNTech SE바이오엔텍

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 28.	UBS	—	Upgrade	Neutral → Buy	—	UBS: Neutral → Buy
2026. 05. 22.	Bernstein	—	Initiate coverage	— → Market Perform	—	Bernstein: Market Perform
2026. 05. 07.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy
2026. 05. 06.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 04. 27.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 04. 10.	Morgan Stanley	—	Maintain	Overweight → Overweight	—	Morgan Stanley: Overweight